GlassScriptPhysician profile
Alexandra L Bewley
NPI 1851772958
$2,383.58
in general payments reported to CMS, 2019-2025
27 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.35 · 2022: $516 · 2023: $480 · 2024: $939 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.32 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Janssen Pharmaceuticals, INC | $207.33 | 2021-2024 | Xarelto |
| Genzyme Corporation | $171.88 | 2024-2025 | |
| Csl Behring | $157.06 | 2022-2023 | Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $149.08 | 2024-2025 | Takhzyro, Hyqvia |
| Shionogi INC | $121.24 | 2022-2023 | Fetroja |
| Vifor Pharma, INC. | $120.23 | 2022-2023 | Veltassa |
| Pfizer INC. | $108.14 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $105.72 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $97.62 | 2024-2025 | Xembify |
| Glaxosmithkline, LLC. | $94.73 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.95 | 2021-2022 | |
| Genentech USA, INC. | $75.00 | 2024 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $69.86 | 2022-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.12 | 2022-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $52.65 | 2023 | Arikayce |
| Kaleo, INC. | $51.44 | 2024 | Auvi-Q |
| Ferring Pharmaceuticals INC. | $37.78 | 2023 | Rebyota |
| Amgen INC. | $32.99 | 2023-2024 | Tezspire |
| Gilead Sciences, INC. | $24.08 | 2021 | |
| Abbvie INC. | $21.48 | 2021 | |
| Merck Sharp & Dohme LLC | $18.90 | 2024 | Dificid |
| Biocryst US Sales Co., LLC | $18.07 | 2025 | Orladeyo |
| Alexion Pharmaceuticals, INC. | $17.65 | 2023 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $16.69 | 2025 | Voquezna |
| Optinose US, INC. | $16.36 | 2024 | |
| Hikma Pharmaceuticals USA | $13.21 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Bewley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.